Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 15/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31047833 | 1.00 | ADRA1A (0.54) | ADRA1AHRH3 | |
| SCHEMBL18186145 | 0.97 | ADRA1A (0.57) | ADRA1AHRH3 | |
| SCHEMBL16855368 | 0.91 | ADRA1A (0.65) | ADRA1A | |
| SCHEMBL31047863 | 0.91 | ADRA1A (0.65) | ADRA1A | |
| SCHEMBL31047818 | 0.89 | ADRA1A (0.67) | ADRA1A | |
| SCHEMBL16855473 | 0.89 | ADRA1A (0.67) | ADRA1A | |
| SCHEMBL23852178 | 0.87 | ADRA1A (0.55) | ADRA1AHRH3 | |
| SCHEMBL16855256 | 0.87 | ADRA1A (0.61) | ADRA1AHRH3 | |
| SCHEMBL16855418 | 0.80 | ADRA1A (0.81) | ADRA1A | |
| SCHEMBL18186150 | 0.75 | ADRA1A (0.52) | ADRA1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883933-A1 | a2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2021-09-29 | — | — | EP | disclosed |
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-30 | — | — | US | disclosed |
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-30 | — | — | US | disclosed |
| US-20200230136-A1 | SELECTIVE ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS ALONE, OR IN COMBINATION WITH CHYMASE INHIBITORS FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PERIPHERAL ARTERY DISEASES (PAD) | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | US | disclosed |
| US-20200230136-A1 | SELECTIVE ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS ALONE, OR IN COMBINATION WITH CHYMASE INHIBITORS FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PERIPHERAL ARTERY DISEASES (PAD) | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | US | disclosed |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-06-18 | — | — | US | disclosed |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-06-18 | — | — | US | disclosed |
| EP-3083592-B1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES AND THEIR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS | Bayer Pharma AG (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3083592-B1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES AND THEIR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS | Bayer Pharma AG (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3329920-A2 | ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-9944621-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-17 | — | — | US | disclosed |
| US-9944621-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-17 | — | — | US | disclosed |
| US-9944621-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-17 | — | — | US | disclosed |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| WO-2015091414-A2 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230136-A1 | SELECTIVE ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS ALONE, OR IN COMBINATION WITH CHYMASE INHIBITORS FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PERIPHERAL ARTERY DISEASES (PAD) | ADRA2C, ADRB2, ADRA2A | ADRA1A 9/4885HRH3 381/4885 |
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885HRH3 1756/4885 |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 1852/4885HRH3 1700/4885 |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885HRH3 1756/4885 |
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885HRH3 1756/4885 |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885HRH3 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.